Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
The Lancet Oncology2019Vol. 20(8), pp. 1124–1135
Citations Over TimeTop 1% of 2019 papers
Udai Banerji, Carla M.L. van Herpen, Cristina Saura, Fiona Thistlethwaite, Simon Lord, Víctor Moreno, Iain R. Macpherson, Valentina Boni, Christian Rolfo, Elisabeth G.E. de Vries, Sylvie Rottey, Jill J.J. Geenen, Ferry A.L.M. Eskens, Marta Gil-Martín, Ellen C.M. Mommers, N.P. Koper, Philippe Aftimos
Related Papers
- → Mechanisms of Trastuzumab Resistance and Their Clinical Implications(2005)74 cited
- → Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice(2021)37 cited
- → Is there any cumulative dose for trastuzumab?(2014)3 cited
- → Cytotoxic Effects of Seleno-Trastuzumab, Trastuzumab (Herceptin) and T-DM-1 (Kadcyla) on Trastuzumab Resistant JIMT-1 Breast Cancer Cells(2014)
- Cardiac toxicity of trastuzumab in elderly patients with breast cancer(2016)